Ultimovacs ASA Valuation
| ULTI Stock | NOK 1.98 0.05 2.46% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Ultimovacs ASA has a current Real Value of 1.7 per share. The regular price of the company is 1.98. Our model measures the value of Ultimovacs ASA from inspecting the company fundamentals such as EBITDA of (161.69 M), return on equity of -0.33, and Shares Outstanding of 34.4 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Ultimovacs ASA's price fluctuation is dangerous at this time. Calculation of the real value of Ultimovacs ASA is based on 3 months time horizon. Increasing Ultimovacs ASA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ultimovacs stock is determined by what a typical buyer is willing to pay for full or partial control of Ultimovacs ASA. Since Ultimovacs ASA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ultimovacs Stock. However, Ultimovacs ASA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.98 | Real 1.7 | Hype 1.98 | Naive 1.88 |
The intrinsic value of Ultimovacs ASA's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Ultimovacs ASA's stock price.
Estimating the potential upside or downside of Ultimovacs ASA helps investors to forecast how Ultimovacs stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ultimovacs ASA more accurately as focusing exclusively on Ultimovacs ASA's fundamentals will not take into account other important factors: Ultimovacs ASA Total Value Analysis
Ultimovacs ASA is at this time expected to have takeover price of 3.35 B with market capitalization of 4.11 B, debt of 457 K, and cash on hands of 1.85 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ultimovacs ASA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.35 B | 4.11 B | 457 K | 1.85 M |
Ultimovacs ASA Asset Utilization
One of the ways to look at asset utilization of Ultimovacs is to check how much profit was generated for every dollar of assets it reports. Ultimovacs ASA has a negative utilization of assets of -0.2 %, losing 0.002021 for each kroner of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each kroner of assets it has. In other words, asset utilization of Ultimovacs ASA shows how discouraging it operates for each kroner spent on its assets.Ultimovacs ASA Ownership Allocation
Ultimovacs ASA shows a total of 34.4 Million outstanding shares. Ultimovacs ASA maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Ultimovacs ASA Profitability Analysis
Net Loss for the year was (164.72 M) with profit before overhead, payroll, taxes, and interest of 0.About Ultimovacs ASA Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Ultimovacs ASA. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Ultimovacs ASA based exclusively on its fundamental and basic technical indicators. By analyzing Ultimovacs ASA's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Ultimovacs ASA's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ultimovacs ASA. We calculate exposure to Ultimovacs ASA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ultimovacs ASA's related companies.Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
8 Steps to conduct Ultimovacs ASA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Ultimovacs ASA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Ultimovacs ASA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Ultimovacs ASA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Ultimovacs ASA's revenue streams: Identify Ultimovacs ASA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Ultimovacs ASA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Ultimovacs ASA's growth potential: Evaluate Ultimovacs ASA's management, business model, and growth potential.
- Determine Ultimovacs ASA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Ultimovacs ASA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.